FDA Approves Blueprint Medicines’ Rare Blood Disorder Treatment

News
Article

Blueprint Medicines’ avapritinib has been approved by FDA for the treatment of indolent systemic mastocytosis.

Blueprint Medicines announced FDA approval of Ayvakit (avapritinib) for treatment of adults with indolent systemic mastocytosis (ISM), a rare hematologic disorder, on May 22, 2023. Avapritinib, a tyrosine-kinase (KIT) inhibitor that selectively inhibits KIT D816V, was previously approved for the treatment of systemic mastocytosis (1). According to a company press release, it is the first and only FDA-approved medicine designed to treat ISM.

FDA’s approval is based in part on findings from a Phase II, double-blind, placebo-controlled clinical trial (PIONEER). Patients who received avapritinib demonstrated significant improvements versus placebo in both the primary and all key secondary endpoints, improving overall symptoms and measures of mast cell burden.

"After decades of caring for people with indolent systemic mastocytosis, I have seen firsthand its profound impact on patients' underlying mast cell burden, symptoms, physical and mental health, and ability to work and participate in daily activities," said Cem Akin, professor of Medicine at the University of Michigan, and an investigator on the Phase II clinical trial. "Despite the use of multiple supportive care treatments, a considerable number of patients with indolent systemic mastocytosis continue to experience a substantial disease burden. [Avapritinib] advances the treatment of indolent systemic mastocytosis by targeting KIT D816V, the primary underlying cause of the disease, and establishes a new standard of care for a broad population of patients with this disorder. [Avapritinib] delivered statistically significant and consistent clinical improvements in the PIONEER trial, and based on these practice-changing data, I feel a tremendous sense of hope for the future for all those affected by the disease."

Source: Blueprint Medicines

1. FDA. FDA Approves Avapritinib for Advanced Systemic Mastocytosis. Press Release, June 16, 2021.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes